Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - dolutegravir sodium, lamivudine , tenofovovir disoproxil fumarate - oral tablet - dolutegravir 50mg, lamivudine 300mg and tenofovir disoproxil fumerate 300mg

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir sodium, quantity: 10.5 mg (equivalent: dolutegravir, qty 10 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; sodium stearylfumarate; mannitol; microcrystalline cellulose; povidone; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir sodium, quantity: 26.3 mg (equivalent: dolutegravir, qty 25 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; sodium stearylfumarate; mannitol; microcrystalline cellulose; povidone; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; iron oxide yellow - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir sodium, quantity: 5.26 mg (equivalent: dolutegravir, qty 5 mg) - tablet, dispersible - excipient ingredients: sodium starch glycollate; mannitol; microcrystalline cellulose; povidone; purified water; silicified microcrystalline cellulose; crospovidone; calcium sulfate dihydrate; sucralose; sodium stearylfumarate; hypromellose; macrogol 400; titanium dioxide; flavour - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

United States - English - NLM (National Library of Medicine)

viiv healthcare company - dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), rilpivirine hydrochloride (unii: 212wax8kdd) (rilpivirine - unii:fi96a8x663) - dolutegravir 50 mg - juluca is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of juluca. juluca is contraindicated in patients:    •    with previous hypersensitivity reaction to dolutegravir or rilpivirine [see warnings and precautions (5.1)] .    •    receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see drug interactions (7)] .    •    receiving other coadministered drugs in table 1 that significantly decrease rilpivirine plasma concentrations [see drug interactions (7), clinical pharmacology (12.3)] . drug class contraindicated drugs in class clinical comment antia

United States - English - NLM (National Library of Medicine)

viiv healthcare company - dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1) - dolutegravir 10 mg - tivicay and tivicay pd are indicated in combination with other antiretroviral agents for the treatment of hiv‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [insti]-naïve) aged at least 4 weeks and weighing at least 3 kg [see microbiology (12.4)]. tivicay is indicated in combination with rilpivirine as a complete regimen for the treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. tivicay and tivicay pd are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to tivicay or tivicay pd during pregnancy. healthcare providers

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - dolutegravir sodium 52.6mg equivalent to dolutegravir 50 mg;  ;  ;   - film coated tablet - 50 mg - active: dolutegravir sodium 52.6mg equivalent to dolutegravir 50 mg       excipient: mannitol microcrystalline cellulose opadry yellow 85f92461 povidone sodium starch glycolate sodium stearyl fumarate - tivicay is indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children over 12 years of age and weighing 40 kg or more.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; sodium stearylfumarate; mannitol; microcrystalline cellulose; povidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

Kenya - English - Pharmacy and Poisons Board

dolutegravir sodium - film-coated tablet - dolutegravir sodium tablet for oral suspension… - dolutegravir

Kenya - English - Pharmacy and Poisons Board

lupin limited 3rd floor, kalpataru inspire, off w. e. highway, - dolutegravir, lamivudine and tenofovir disoproxil… - tablet - dolutegravir, lamivudine and tenofovir disoproxil… - dolutegravir